Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
Etiology of Acute Otitis Media in Children Less Than 5 Years of Age A Pooled Analysis of 10 Similarly Designed Observational Studies
| Indexado |
|
||||
| DOI | 10.1097/INF.0000000000001420 | ||||
| Año | 2017 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Abstract
Conclusions: Spn and Hflu remain the leading otopathogens in all populations examined. While associated with overlapping symptoms and severity, they exhibit some differences in their likelihood to cause disease in specific subpopulations.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Van Dyke, Melissa K. | Mujer |
GSK Vaccines - Bélgica
GlaxoSmithKline Pharmaceuticals SA/NV - Bélgica GlaxoSmithKline plc. - Reino Unido |
| 2 | Pircon, Jean-Yves | Hombre |
GSK Vaccines - Bélgica
GlaxoSmithKline Pharmaceuticals SA/NV - Bélgica GlaxoSmithKline plc. - Reino Unido |
| 3 | Cohen, Robert | Hombre |
CHI Creteil - Francia
UPEC - Francia Centre Hospitalier Intercommunal Creteil - Francia |
| 4 | Madhi, Shabir | Hombre |
Univ Witwatersrand - República de Sudáfrica
University of Witwatersrand - República de Sudáfrica University of the Witwatersrand, Johannesburg - República de Sudáfrica University of the Witwatersrand Faculty of Health Sciences - República de Sudáfrica |
| 5 | Rosenblut, Andres | Hombre |
Hospital Dr Sotero del Rio - Chile
|
| 6 | Macias-Parra, Mercedes | Mujer |
Inst Nacl Pediat Secretaria Salud SSA - México
Instituto Nacional de Pediatría - México |
| 7 | Al-Mazrou, Khalid | Hombre |
King Saud Univ - Arabia Saudí
King Saud Bin Abdulaziz Univ Hlth Sci - Arabia Saudí King Saud University - Arabia Saudí |
| 8 | Grevers, Gerhard | Hombre |
ENT Ctr - Alemania
Ent-Center - Alemania |
| 9 | Lopez, Pio | - |
Ctr Estudios Infectol Pediat - Colombia
Centro de Estudios en Infectología Pediátrica - Colombia |
| 10 | Naranjo, Laura | Mujer |
GSK Biol - Panamá
GlaxoSmithKline plc. - Reino Unido GlaxoSmithKline plc. - Panamá |
| 11 | Pumarola, Felix | Hombre |
Hosp Univ Vall dHebron - España
Hospital Universitari Vall d'Hebron - España |
| 12 | Sonsuwan, Nuntigar | - |
Chiang Mai Univ - Tailandia
Faculty of Medicine, Chiang Mai University - Tailandia |
| 13 | Hausdorff, William P. | Hombre |
GSK Vaccines - Bélgica
GlaxoSmithKline Pharmaceuticals SA/NV - Bélgica GlaxoSmithKline plc. - Reino Unido |
| Fuente |
|---|
| Novartis |
| GSK |
| Bayer |
| Pfizer |
| AstraZeneca |
| Sanofi Pasteur |
| MSD |
| Medscape |
| GSK group of companies |
| SP-MSD |
| Agradecimiento |
|---|
| W.P.H. was an employee of the GSK group of companies at the time of initial development of this article and own stocks/stock options of GSK group of companies. M.K.V.D. and J-Y.P. are currently employees of the GSK group of companies. R.C. declares having received money for consultancy and payment for lectures and his institution having received grants from GSK, Pfizer, Novartis, SP-MSD and AstraZeneca. S.A.M. declares his institution having received money for the conduct of the study in South Africa included in this pooled analysis. He reports personal fees for development of educational presentations from Medscape (about PCV, rotavirus and pertussis topics) consultancy in advisory board from GSK and Pfizer, payment for lectures from Sanofi Pasteur (in relation with Hexaxim), GSK (pneumococcal and rotavirus vaccines) and Pfizer (PCV), and his institution received grants from Novartis (GBS) and GSK (PCV). A.R. reports him and his institution having received grants for the conduct of the study in Chile included in this pooled analysis. M.M.P. reports grants to her institution for participation in protocols of trials from the following companies: Novartis, Sanofi Pasteur, Bayer, MSD (phase III), GSK (phase III and Pharmacoeconomics) and Pfizer (phase IIb and phase III). She declares having received consulting fees for lectures from Sanofi Pasteur, support for travel to meeting (Congresses) from GSK, Sanofi Pasteur, Pfizer and MSD, and fees for participation to advisory boards from GSK and Novartis. K.A-M. declares his institution having received grants for the conduct of the study in Saudi Arabia included in this pooled analysis, and he received support for travel to meeting from the GSK group of companies. P.L. declares his institution having received a grant from GSK for the conduct of the study in Colombia included in this pooled analysis. L.N. declares her institution having received money for the conduct of the study in Venezuela included in this pooled analysis. She is currently an employee of the GSK group of companies. N.S. declares having received grant, consultancy fees, payment for lectures and support for travel to meetings during conduct of the study in Thailand included in this pooled analysis. W.P.H. is a co-holder of a patent for 13-valent PCV licensed to Pfizer/Wyeth, but receives no royalties as per industry practice. He is currently an independent consultant. R.C. (France), S.A.M. (South Africa), A.R. (Chile), M.M.P. (Mexico), K.A-M. (Saudi Arabia), G.G. (Germany), P.L. (Colombia), L.N. (Venezuela), F.P. (Spain) and N.S. (Thailand) were investigators of the studies included in this pooled analysis. G.G. and F.P. have no conflicts of interest to disclose. |
